Mild cognitive impairment or Alzheime's disease Alzheimer disease, cognitive impairment
Conditions
Interventions
Sponsors
Matsuda Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those who have cognitive impairment suspected of having MCI and early AD based on the diagnostic criteria of NIA-AA or DSM-5 2) 40 to 90 years old, regardless of gender 3) A person who can obtain written consent from the person or his / her substitute. 4) MRI imaging including 3DT1 weighted image has already been performed within 90 days at the time of obtaining consent.
Exclusion criteria
Exclusion criteria: 1) Those who have gross lesions (brain tumor, cerebral vascular malformation, cortical infarction, etc.) on brain MRI. 2) Those who have serious complications, or those who have a history of these and are judged by the investigator and the investigator to be ineligible for this study. 3) In addition, those who are judged by the principal investigator and the investigator to be ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Quantitative evaluation of amyloid beta protein with 18F-NAV4694 PET 2)Quantitative evaluation of tau protein with 18F-MK6240 PET 3)Structural network analysis and production of each parametric image from 3D T1WI brain MRI 4)Correlation analysis of each structural network parametric image with accumulation of Abeta and tau protein | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of 18F-MK6240 and 18F-NAV4694 | — |
Contacts
Public ContactHiroshi Matsuda
The Research Institute for Neuroscience Southern Tohoku Drug Discovery and Cyclotron Research Center
Outcome results
None listed